Walvax Biotech Showcases Innovative Vaccines at the 10th China-South Asia Expo to Empower Regional Health Collaboration and Shape a New Industrial Landscape in South and Southeast Asia

June 11, No. 10th China - The South and Southeast Asia Expo and the 30th China Kunming Import and Export Commodities Fair grandly opened at the Dianchi International Convention and Exhibition Center in Kunming, Yunnan. Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") made a significant appearance with its full range of vaccine products. Leveraging Yunnan's strategic location as a gateway to South and Southeast Asia, Walvax continues to deepen regional public health cooperation and supports the accelerated development of a highland for the greater health industry in South and Southeast Asia.

This Edition of the South and Southeast Asia Expowith“United Collaboration, Joint Development”forSubject, Exhibition DurationOver six days, more than 60 countries, regions, and international organizations registered to exhibit, achieving full coverage of South Asia, Southeast Asia, and RCEP member states. Building on the existing South Asia Pavilion, Southeast Asia Pavilion, Overseas Pavilion, and Domestic Cooperation Pavilion, this edition of the CSBIE further segmented industrial tracks, establishing a total of 13 unitsSpecialized Exhibition Halls: Focusing on Trade in Services, Green Energy, Healthcare and Wellness, and Cultural Tourism, Serving as a Key Window for External Display, Exchange, and the Deepening of Economic and Trade Cooperation.

No.Venue of the 10th China-South Asia Expo: Kunming Dianchi International Convention and Exhibition Center

(Image sourceXinhua News Agency Photo by Chen Xinbo）

As a high-tech biopharmaceutical enterprise specializing in human vaccines and integrating research and development, production, and sales, Walvax has been deeply engaged in the R&D of innovative vaccines for many years, having established a portfolio encompassing bacterial vaccines and recombinant protein vaccines,Leveraging four core technology platforms, including mRNA vaccines and recombinant adenovirus vector vaccines, the company has obtained marketing approval for a total of eight vaccine products (comprising 14 specifications) to date, making it the enterprise with the most significant comparative advantage in China in terms of the number of independently developed vaccine products and portfolio diversity.

At this year's South China Expo, the company focused on showcasing13-valent Pneumococcal Conjugate Vaccine (Walvax)®), bivalentHPV Vaccine (Walvax)®) and other core products. The company is the first in China and the second globally to independently develop and successfully launchWalvax, the manufacturer of the 13-valent pneumococcal conjugate vaccine, has consistently maintained a leading market share in China since 2021, establishing a robust health barrier for vulnerable populations such as infants and young children. The company’s independently developed bivalent human papillomavirus (HPV) vaccine received World Health Organization (WHO) Prequalification (PQ) certification in August 2024, with its production management system meeting WHO GMP standards. Actively responding to the national “Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030),” Walvax continues to participate in government-sponsored procurement programs aimed at public benefit, thereby making high-cost-performance vaccine products accessible to a broader population.

Walvax Booth

Leveraging its technological and industrialization advantages, Walvax actively practices“Product Export + Technology Export” Dual-Drive Globalization Strategy, Seizing the Cooperation Opportunities of the "Belt and Road Initiative", Focusing on Overseas Developing Countries and Regional Markets, with Differentiated Product Portfolios Precisely Meeting the Needs of Emerging Markets. To Date, the Company’s Vaccine Products Have Cumulatively Been Exported to 27countries and regions, covering regional markets in Southeast Asia, South Asia, Central Asia, and Africa. Meanwhile, the company continues to advance its overseas localization efforts, newly launching technology transfer projects in multiple countries and regions including Egypt and Malaysia, which will effectively help enhance the independent vaccine manufacturing capabilities in Africa, Southeast Asia, and other regions.

During the exhibition, Xu Jianbin, Secretary of the Party Leadership Group and Director of the Yunnan Provincial Health Commission; He Menghuang, Member of the Party Leadership Group and Deputy Director of the Yunnan Provincial Health Commission; Yang Meiqiong, Secretary of the Party Leadership Group and Director of the Yuxi Municipal Science and Technology Bureau; and their delegation visited the Walvax booth for inspection and guidance. They fully affirmed the company’s commitment to establishing its roots in Yunnan, leveraging its locational advantages to radiate into surrounding regions, and its strategic planning and practical achievements in deeply cultivating the big health industry. Dong Shaozhong, Vice Chairman of Walvax, accompanied the delegation and provided a comprehensive introduction to the company’s latest technological achievements and industrialization layout. The two parties engaged in in-depth exchanges on vaccine R&D innovation, industrial development, and international expansion, fostering a harmonious and enthusiastic atmosphere.

Xu Jianbin, Secretary of the Party Leadership Group and Director of the Yunnan Provincial Health Commission, Visited Walvax’s Booth for Guidance

Yang Meiqiong, Party Secretary and Director of the Yuxi Municipal Science and Technology Bureau, Visited and Provided Guidance at the Walvax Booth